Good post Hipity and another good post Mark......great analogy of the razor blade & blunt object Hip......
it's possible....considering it's at 5.45 in AH. Considerable resistance at 6.00 to 6.10 but buying pressure is heavy...I will take some profits this week...
Mark - Most longs who were buying aggressively in the .40's, .50's & .60's probably look at the trading today as a non-event. I know I do. Matter of fact, if it was a year ago - Ino would have dropped 15 to 20%. So we have mellowed a bit since then. Traders, MM's & hedgies move this because they can. Without any volatility, they don't make their money. I have no problem with it because in the end, the science & management will be what moves this thing........
I believe FB & Twitter will be scarce remnants of what they are now.in the next 5 - 10 years. Look at the demo's of FB........they are losing the younger crowd I significant numbers. So where's their future market? These social sites have to deal with a fickle young market base constantly looking for the next cool thing. Good luck with that........jmho
glta ino longs
Navb does not make medical equipment & appliances. Navb has an approved product called Lymphoseek which is the new SOC for mapping cancer in the lymph nodes. Navidea is fine but Navidea the stock is broken for now.......
Now that is funny & bizarre at the same time. I went back to the Fierce Biotech article to see if I had just dreamed the quote up or got it from them and I couldn't find anything. Maybe I saw it somewhere else or from the brief release. So - no problem.....I probably stole it from you :). Just turned 62 and although I'm in great shape - my memory is leaving me! Keep up the good work and gl.......Hopefully, a few of us west coasters can get together down the road.......Go Ino
Kyle......great article - well written. I must say you stole my tag line word for word from my post #9513 (Johan31) on ihub.........oh well - great minds........ :)
Biotechs got hammered today: BOSTON (TheStreet) -- Biotech stocks sold off the most in two years Tuesday amidst growing investor concerns that the U.S. government shutdown and looming debt ceiling clash are far from resolved.
The iShares Nasdaq Biotechnology (IBB), the ETF tracking the biotech sector, fell 4.35% to $198.75 Tuesday, far outpacing the 1.23% loss in the S&P 500. The last time the IBB dropped this much in a single day was Oct. 3, 2011, when it lost 4.5%.
Going into today, the IBB was up 52%, so investors appeared to be locking in profits from winning drug and biotech stocks, perhaps in anticipation of a broader market sell off due to the fiscal gridlock in Washington D.C.
There has been much debate recently about whether the surging biotech stock valuations was causing a bubble. That debate will only intensify following today's significant. It remains to be seen if Tuesday's downturn is the start of a major valuation correction in biotech or just a pause in buying that will continue through year's end.
Acadia Pharmaceuticals (ACAD_) and Insys Therapeutics (INSY_) -- two of biopharma's best-performing stocks in 2013 -- were among the stocks getting hit the most on Tuesday. Acadia lost 15% to $23.30 while Insys fell 15% to $41.63.
Other double-digits losers today included Geron (GERN_) (-13%), Prosensa (RNA_) (-11%) and Idenix Pharmaceuticals (IDIX_) (-16%.)
Among big-cap biotechs, Celgene (CELG_) lost 3%, Biogen Idec (BIIB_) fell 4%, Amgen (AMGN_) was down 2% and Gilead Sciences (GILD_) shed 3.5%.
To put today's biotech selling in further perspective, the IBB has dropped 3% or more in a single day only four times in the past two years. The last occurrence was on Aug. 27. Before that, the IBB lost 3% on Oct. 19, 2012 and June 1, 2012.
oh yes....give me the Baker brothers. Been waiting a long time to see them get involved
remember six months or so ago, Inovio had an employment add looking for someone who was a 3d printer skilled engineer type. Led a few people to speculate that they were going to manufacture their own injection device. If that does come to fruition - that would greatly reduce the costs of vaccine dosing also....
Look forward to it Mark....The Influenza trial is one of the big three in Inovio's arsenal imo. There are 3 that are internally funded. 1) Cervical Dysplasia/Hpv now in Phase2 - VGX3100; 2) Influenza Universal - VGX3400x Phase 1 concluding; 3) Breast & Lung Cancer - Ino1400 ready to start Phase1..... This hTert Breast & Lung Cancer Therapeutic trial could be the biggest thing in their bag of tricks. A successful trial for breast cancer will put Inovio in the stratosphere as far as PPS & MC go. I hope they keep this in-house but fear they may partner this out like the prostate trials. The amount of press that would follow a promising breast cancer treatment would make Inovio a household name. Bigger than the influenza and the HPV indications imo....
FWIW.........Shareholders of record are those entities that actually are in possession of the stock certificates. Unless you have requested the actual certificates from your broker - your broker is the shareholder of record. So it's all the institutions, hedgies, possible insiders and VC's who hold the certificates who are the ones that are considered shareholders of record.
I like cldx also even though I don't have any. Have some NVAX..... and NAVB for a long term hold......